** Shares of drug developer GH Research GHRS.O rise 90% to $20.14 premarket

** Co's therapy for treatment-resistant depression meets main goal of mid-stage trial by reducing the severity of the disease as measured on a widely used scale

** GHRS says 57.5% of patients on the therapy, GH001, had less severe disease at 8 days

** GH001 also meets all secondary goals of the trials, GHRS adds

** GHRS rose 20.7% in 2024

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))